Mereo BioPharma Group (LTS:0A9G) 10-Year Share Buyback Ratio : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Mereo BioPharma Group's current 10-Year Share Buyback Ratio was 0.00%.

LTS:0A9G's 10-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -12.6
* Ranked among companies with meaningful 10-Year Share Buyback Ratio only.

Competitive Comparison of Mereo BioPharma Group's 10-Year Share Buyback Ratio

For the Biotechnology subindustry, Mereo BioPharma Group's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group's 10-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Mereo BioPharma Group 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Mereo BioPharma Group (LTS:0A9G) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Mereo BioPharma Group 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

MREO:USA MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines